Filgrastim biosimilar - Aequus/CTI BioPharma

Drug Profile

Filgrastim biosimilar - Aequus/CTI BioPharma

Alternative Names: AQB-101; Filgrastim-biosimilar-Aequus/CTI BioPharma; G-CSF-Aequus/CTI BioPharma; Granulocyte colony stimulating factor

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aequus BioPharma
  • Developer Aequus BioPharma; CTI BioPharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Neutropenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia in USA (SC, Injection)
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 30 May 2012 Pharmacokinetics data from preclinical studies in Neutropenia released by Aequus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top